The potential of neuroprotection in glaucoma treatment

Current Opinion in Ophthalmology

Volumn 10, Issue 2, 1999, Pages 82-92

  Osborne, Neville N ^a   Chidlow, Glyn ^a   Nash, Mark S ^a   Wood, John P M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMINOGUANIDINE; AURINTRICARBOXYLIC ACID; BASIC FIBROBLAST GROWTH FACTOR; BETAXOLOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CYCLOHEXIMIDE; DACTINOMYCIN; DIZOCILPINE; FLUNARIZINE; FLUPIRTINE; GANGLIOSIDE GM1; GLUTAMIC ACID; HYDROCORTISONE; KYNURENINE; MEMANTINE; N(G) NITROARGININE; N5 (1 IMINOETHYL)ORNITHINE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIN 4; PROTEOCHONDROITIN SULFATE; SELEGILINE; TIRILAZAD; VASOACTIVE INTESTINAL POLYPEPTIDE;

APOPTOSIS; ARTICLE; DRUG MECHANISM; GLAUCOMA; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA GANGLION CELL; VISUAL FIELD DEFECT;

ANIMALS; CELL DEATH; GLAUCOMA; HUMANS; NEUROPROTECTIVE AGENTS; RETINAL GANGLION CELLS; VISUAL FIELDS;

EID: 0032782221     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199904000-00002     Document Type: Article

References (137)

1. 1 Bathija R, Gupta N, Zangwill L, Weinreb RN: Changing definition of glaucoma. J Glaucoma 1998, 7:165-169. The authors review a selection of literature from the past 15 years concerning open angle glaucoma in an attempt to clarify the definition of this condition. They conclude that there is an urgent need to obtain and adhere to a consensus definition.
2. 2 Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL: Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994, 117:603-624.
3. 3 Flammer J: The vascular concept of glaucoma. Surv Ophthalmol 1994, 38 (suppl):S3-6.
4. 4 Douglas GR: Pathogenetic mechanisms of glaucoma not related to intraocular pressure. Curr Opin Ophthalmol 1998, 9:34-38.
5. 5 Quigley HA: Recognizing structural damage to the optic nerve head and nerve fiber layer in glaucoma. Am J Ophthalmol 1998, 125:563.
6. 6 Fechtner RD, Weinreb RN: Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol 1994, 39:23-42.
7. 7 Hernandez MR, Ye H: Glaucoma: changes in extracellular matrix in the optic nerve head. Ann Med 1993, 25:309-315.
8. 8 Hernandez MR, Pena JD: The optic nerve head in glaucomatous optic neuropathy. Arch Ophthalmol 1997, 115:389-395.
9. 9 Nickells RW: Retinal ganglion cell death in glaucoma: the how, the why and the maybe. J Glaucoma 1996, 5:345-356.
10. 10 Nickells RW: Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv Ophthalmol 1998, in press. This paper summarizes the current knowledge on apoptosis and how this process may contribute to retinal ganglion cell death. The author concentrates on the roles of p53 and bcl-2-related genes and caspase enzymes and also discusses the importance of mitochondria in these processes.
11. 11 McKinnon SJ: Glaucoma, apoptosis and neuroprotection. Curr Opin Ophthalmol 1997, 8:28-37. This review focuses on the role of apoptosis in retinal ganglion cell loss and describes how loss of these neurones constitutes the final common pathway in glaucoma. Mechanisms of death and means of identification of specific apoptosis-related events are discussed.
12. 12 Chen DF, Tonegawa S: Why do mature CNS neurons of mammals fail to re-establish connections following injury: functions of Bcl-2. Cell Death Differ 1998, 5:816-822. The authors describe the mechanisms influencing neuronal axon regeneration. Failure of axons to elongate or regenerate is described as being related to both the formation of glial scar and the function of the protooncogene protein product Bcl-2.
13. 13 Varela HJ, Hernandez MR: Astrocyte responses in human optic nerve head with primary open-angle glaucoma. J Glaucoma 1997, 6:303-313. By employing paraformaldehyde-fixed, paraffin-embedded sections from both the retinas of both control subjects and patients with primary open-angle glaucoma, these authors describe the existence of two distinct types of astrocytes in the optic nerve head. They show that in primary open-angle glaucoma, type 1B astrocytes exhibit both a greater immunoreactivity to GFAP and N-CAM and an altered morphology. These astrocyte responses are hypothesized to have a pathogenic significance for glaucomatous optic nerve neuropathy.
14. 14 Osborne NN, Ugarte M, Chao M, Chidlow G, Bae JH, Wood JPM, Nash MS: Neuroprotection in relation to retinal ischaemia and relevance to glaucoma. Surv Ophthalmol 1998, in press. This comprehensive review covers known literature concerning ganglion cell loss in glaucoma and other related conditions. The roles of apoptosis, ischemia, and glutamate in ganglion cell death and optic cupping are discussed and a wideranging review of neuroprotective strategies is presented.
15. 15 Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA: Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996, 114:299-305.
16. 16 Otori Y, Wei JY, Bamstable CJ: Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1998, 39:972-981.
17. 17 Sucher NJ, Lipton SA, Dreyer EB: Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 1997, 37:3483-3493. This paper describes the involvement of glutamate receptors, particularly of the NMDA type, and calcium in retinal ganglion cell death. The potential use of antagonists for these receptors to prevent glaucomatous damage is also discussed.
18. 18 Delbarre G, Delbarre B, Calinon F, Ferger A: Accumulation of amino acids and hydroxyl free radicals in brain and retina of gerbil after transient ischemia. J Ocul Pharmacol 1991, 7:147-155.
19. 19 Müller A, Villain M, Bonne C: The release of amino acids from ischemic retina. Exp Eye Res 1997, 64:291-293.
20. 20 Jay JL, Allan D: The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye 1989, 3:528-535.
21. 21 Yoles E, Schwartz M: Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol 1998, 42:367-372. The process of secondary degeneration of neurones after an initial lesion and the possibilities for neuroprotection within this paradigm are discussed.
22. 22 Flammer J, Orgul S: Optic nerve blood-flow abnormalities in glaucoma. Prog Retinal Eye Res 1998, 17:267-289. This review describes the importance of the vascular theory of glaucomatous optic nerve damage. The authors conclude that the main cause for the circulation disturbance in glaucoma seems to be a vascular dysregulation leading to local vasospasm and to systemic hypotension.
23. 23 Caprioli J: Neuroprotection of the optic nerve in glaucoma. Acta Ophthalmol 1997, 75:364-367. The author discusses the importance of both pressure and vascular theories of ganglion cell damage. Neuroprotection strategies outlined include blockade of calcium channels or glutamate receptors, use of antioxidants or stress-response proteins, and inhibition of apoptosis or nitric oxide synthesis.
24. 24 Levin LA: Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv Ophthalmol 1998, in press. Possible mechanisms of ganglion cell death are described along with the importance of both apoptosis and the timing and degree of optic axon injury. Candidate genes that produce enzymes to counteract reactive oxygen species-induced damage are related to the possibilities of neuroprotection.
25. 25 Zivin JA: Neuroprotective therapies in stroke. Drugs 1997, 54(suppl 3):83-88; discussion 88-89.
26. 26 The European Ad Hoc Consensus Group: Neuroprotection as initial therapy in acute stroke. Third Report of an Ad Hoc Consensus Group Meeting. Cerebrovasc Dis 1998, 8:59-72.
27. 27 Dyker AG, Lees KR: Duration of neuroprotective treatment for ischemic stroke. Stroke 1998, 29:535-542.
28. 28 del Zoppo GJ, Wagner S, Tagaya M: Trends and future developments in the pharmacological treatment of acute ischaemic stroke. Drugs 1997, 54:9-38. The pathologic situations involved in stroke are described along with the latest thoughts on treatment regimens that may be employed, such as neuroprotection, inhibition of inflammation, and arterial recanalization.
29. 29 Osborne NN: Neuroprotection to the retina: relevance in glaucoma. In Risk Factors and Neuroprotection in Glaucoma. Edited by Drance SM. Amsterdam: Kugler Publications; 1997:139-155. This overview relates retinal ischemia to glaucoma, describing the selectivity of cellular damage in both cases as weli as reviewing the use of various animal models and discussing therapeutic strategies for the treatment of ischemia/reperfusion injury.
30. 30 Anderson RS, O'Brien C: Psychophysical evidence for a selective loss of M ganglion cells in glaucoma. Vision Res 1997, 37:1079-1083.
31. 31 Robin AL, Barnebey HS, Harris A, Osborne NN: Glaucoma management: beyond intraocular pressure. Ophthamol Times 1997, 22:S1-S23. This paper relates the round-table discussion of four researchers on the subject of glaucoma management and gives an insight into the possible directions of study for the immediate future.
32. 32 Siesjo BK: Pathophysiology and treatment of focal cerebral ischemia: part I: pathophysiology. J Neurosurg 1992, 77:169-184.
33. 33 Bittigau P, Ikonomidou C: Glutamate in neurologic diseases. J Child Neurol 1997, 12:471-485.
34. 34 Kristian T, Siesjo BK: Calcium in ischemic cell death. Stroke 1998, 29:705-718.
35. 35 Baldridge WH: Optical recordings of the effects of cholinergic ligands on neurons in the ganglion cell layer of mammalian retina. J Neurosci 1996, 16:5060-5072.
36. 36 Araki CM, Pires RS, Britto LR, Lindstrom JM, Karten HJ, Hamassaki Britto DE: Differential co-localization of nicotinic acetylcholine receptor subunits with calcium-binding proteins in retinal ganglion cells. Brain Res 1997, 774:250-255.
37. 37 Ogurusu T, Eguchi G, Shingai R: Localization of gamma-aminobutyric acid (GABA) receptor rho 3 subunit in rat retina. Neuroreport 1997, 8:925-927.
38. C receptors confer distinct temporal properties to retinal synaptic responses. J Neurophysiol 1998, 79:3157-3167.
39. C receptors to acetylcholine release and directional selectivity in the rabbit retina. Vis Neurosci 1997, 14:939-948.
40. 40 Wagner HJ, Luo BG, Ariano MA, Sibley DR, Stell WK: Localization of D2 dopamine receptors in vertebrate retinae with anti-peptide antibodies. J Comp Neurol 1993, 331:469-481.
41. 41 Nguyen Legros J, Simon A, Caille I, Bloch B: Immunocytochemical localization of dopamine D1 receptors in the retina of mammals. Vis Neurosci 1997, 14:545-551.
42. 42 Veruki ML: Dopaminergic neurons in the rat retina express dopamine D2/3 receptors. Eur J Neurosci 1997, 9:1096-1100.
43. 43 Brunken WJ, Jin XT, Pis-Lopez AM: The properties of the serotonergic system in the retina. In Progress in Retinal Research. Edited by Osborne NN, Chader GJ. Oxford: Pergamon Press; 1993:75-100.
44. 44 Friedlander RM, Yuan J: ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ 1998, 5:823-831.
45. 45 Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-1312. This important review encompasses an overview of the central events in the apoptosis cascade that revolve around the mitochondrion. It is seen that this cellular organelle plays an integral part in a number of key apoptotic processes.
46. 46 Mignotte B, Vayssiere JL: Mitochondria and apoptosis. Eur J Biochem 1998, 252:1-15.
47. 47 Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998, 281:1305-1308. Another comprehensive review that describes the cellular sequelae that form the initiating mechanisms for apoptosis. A number of the receptor systems known to be involved in apoptotic induction are described.
48. 48 Debatin KM, Beltinger C, Bohler T, Fellenberg J, Friesen C, Fulda S, et al.: Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Biochem Soc Trans 1997, 25:405-410.
49. 49 Yen WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, et al.: FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998, 279:1954-1958.
50. 50 Golstein P: Cell death: TRAIL and its receptors. Curr Biol 1997, 7:R750-753.
51. 51 Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kB pathway. Immunity 1997, 7:821-830.
52. 52 Gorman AM, Orrenius S, Ceccatelii S: Apoptosis in neuronal cells: role of caspases. Neuroreport 1998, 9:R49-55.
53. 53 Newmeyer DD, Green DR: Surviving the cytochrome seas. Neuron 1998, 21:653-655.
54. 54 Tong L, Toliver Kinsky T, Taglialatela G, Werrbach Perez K, Wood T, Perez Polo JR: Signal transduction in neuronal death. J Neurochem 1998, 71:447-459.
55. 55 Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME: TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol 1997, 115:1031-1035. A key research paper that describes the presence, in histologic sections of retinas from patients with primary open-angle glaucoma and age-matched controls, of TUNEL labeling as an indicator of cells undergoing apoptosis in the ganglion cell layer. The conclusion is that apoptosis is a mechanism of ganglion cell loss in glaucoma.
56. 56 Okisaka S, Murakami A, Mizukawa A, Ito J: Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol 1997, 41:84-88.
57. 57 Charriaut-Marlangue C, Ben-Ari Y: A cautionary note on the use of the TUNEL stain to determine apoptosis. Neuroreport 1995, 7:61-64.
58. 58 Collins RJ, Harmon BV, Gobe GC, Kerr JF: Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. Int J Radiat Biol 1992, 61:451-453.
59. 59 Raffray M, Cohen GM: Apoptosis and necrosis in toxicology: a continuum or distinct modes of cell death? Pharmacol Ther 1997, 75:153-177. With much research attempting to separately classify necrotic and apoptotic cellular death, this paper reminds researchers to keep in perspective the fact that there seems, in many instances, to be a rather undefinable and certainly not complete distinction between the two processes.
60. 60 Massey SC: Cell types using glutamate as a neurotransmitter in the vertebrate retina. In Progress in Retinal Research. Edited by Osborne NN, Chader GJ. Oxford: Pergamon Press; 1990:399-425.
61. 61 Derouiche A: Possible role of the Müller cell in uptake and metabolism of glutamate in the mammalian outer retina. Vision Res 1996, 36:3875-3878.
62. 62 Yoles E, Schwartz M: Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol 1998, 116:906-910.
63. 63 Billups B, Attwell D: Modulation of non-vesicular glutamate release by pH. Nature 1996, 379:171-174.
64. 64 Agostinho P, Duarte CB, Oliveira CR: Impairment of excitatory amino acid transporter activity by oxidative stress conditions in retinal cells: effect of antioxidants. FASEB J 1997, 11:1 54-163.
65. 65 Rego AC, Santos MS, Oliveira CR: Oxidative stress, hypoxia, and ischemialike conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. J Neurochem 1996, 66:2506-2516.
66. 66 Lagreze WA, Knorle R, Bach M, Feuerstein TJ: Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci 1998, 39:1063-1066.
67. 67 Siliprandi R, Canella R, Carmignoto G, Schiavo N, Zanellato A, Zanoni R, Vantini G: N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis Neurosci 1992, 8:567-573.
68. 68 Vorwerk CK, Kreutz MR, Dreyer EB, Sabel BA: Systemic L-kynurenine administration partially protects against NMDA, but not kainate-induced degeneration of retinal ganglion cells, and reduces visual discrimination deficits in adults rats. Invest Ophthalmol Vis Sci 1996, 37:2382-2392.
69. 69 Vorwerk CK, Hyman BT, Miller JW, Husain D, Zurakowski D, Huang PL, et al.: The role of neuronal and endothelial nitric oxide synthase in retinal excitotoxicity. Invest Ophthalmol Vis Sci 1997, 38:2038-2044.
70. 70 Osborne NN, Herrera AJ: The effect of experimental ischaemia and excitatory ammo acid agonists on the GABA and serotonin immunoreactivities in the rabbit retina. Neuroscience 1994, 59:1071-1081.
71. 71 Osborne NN, Wood J, Muller A: The influence of experimental ischaemia on protein kinase C and the GABAergic system in the rabbit retina. Neuropharmacology 1995, 34:1279-1288.
72. 72 Osborne NN, Schwarz M, Pergande G: Protection of rabbit retina from ischemic injury by flupirtine. Invest Ophthalmol Vis Sci 1996, 37:274-280.
73. 73 Osborne NN, Larsen AK: Antigens associated with specific retinal cells are affected by ischaemia caused by raised intraocular pressure: effect of glutamate antagonists. Neurochem Int 1996, 29:263-270.
74. 74 Lam TT, Siew E, Chu R, Tso MO: Ameliorative effect of MK-801 on retinal ischemia. J Ocul Pharmacol Ther 1997, 13:129-137.
75. 75 Mohand-Said S, Weber M, Hicks D, Dreyfus H, Sahel JA: Intravitreal injection of gangtioside GM1 after ischemia reduces retinal damage in rats. Stroke 1997, 28:617-621.
76. 76 Shibuki H, Katai N, Kuroiwa S, Kurokawa T, Yodoi J, Yoshimura N: Protective effect of adult T-cell leukemia-derived factor on retinal ischemia-reperfusion injury in the rat. Invest Ophthalmol Vis Sci 1998, 39:1470-1477.
77. 77 Kuroiwa S, Katai N, Shibuki H, Kurokawa T, Umihira J, Nikaido T, et al.: Expression of cell cycle-related genes in dying cells in retinal ischemic injury. Invest Ophthalmol Vis Sci 1998, 39:610-617.
78. 78 Yoles E, Muller S, Schwartz M: NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J Neurotrauma 1997, 14:665-675.
79. 79 Gao H, Qiao X, Hefti F, Hollyfield JG, Knusel B: Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury. Invest Ophthalmol Vis Sci 1997, 38:1840-1847.
80. 80 Mansour Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ: Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci USA 1994, 91:1632-1636.
81. 81 Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ: Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995, 36:774-786.
82. 82 Otori Y, Shimada S, Morimura H, Ishimoto I, Tohyama M, Tano Y: Expression of c-fos and c-jun mRNA following transient retinal ischemia: an approach using ligation of the retinal central artery in the rat. Surv Ophthalmol 1997, 42(suppl) 1:S96-104.
83. 83 Otori Y, Shimada S, Tanaka K, Ishimoto I, Tano Y, Tohyama M: Marked increase in glutamate-aspartate transporter (GLAST/GluT-1) mRNA following transient retinal ischemia. Brain Res Mol Brain Res 1994, 27:310-314.
84. 84 Laquis S, Chaudhary P, Sharma SC: The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res 1998, 784:100-104. This study describes total ganglion cell loss at various times following elevated IOP. The importance of this paper to the current review relates to the experimental paradigm employed. In order to raise the IOP, chronic ocular hypertension is induced, by occlusion of rat episcleral veins. It is argued that this model represents a more realistic system to study glaucomatous pathology.
85. 85 Shareef SR, Garcia Valenzuela E, Salierno A, Walsh J, Sharma SC: Chronic ocular hypertension following episcleral venous occlusion in rats. Exp Eye Res 1995, 61:379-382.
86. 86 Schutte M, Chen S, Bayer AU, Wolosin JM, Mittag T: Pathological changes of the rat retina in response to elevated intraocular pressure. Invest Ophthamol Vis Sci 1997, 38:S160.
87. 87 Kent AR, Greene WB, Ragaiey T: Rat model of primary open angle glaucoma. Invest Ophthalmol Vis Sci 1997, 38:S163.
88. 88 Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC: A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res 1997, 64:85-96.
89. 89 Johnson EC, Morrison JC, Farrell S, Deppmeier L, Moore CG, McGinty MR: The effect of chronically elevated intraocular pressure on the rat optic nerve head extracellular matrix. Exp Eye Res 1996, 62:663-674.
90. 90 Morrison JC, Nylander KB, Lauer AK, Cepurna WO, Johnson E: Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma. Invest Ophthalmol Vis Sci 1998, 39:526-531. Another research paper that employs a model that, it is argued, may provide a more relevant means of addressing the possibilities of neuroprotection in glaucoma. Episcleral veins are destroyed in rats by injections of saline, thus increasing the IOP.
91. 91 Selles Navarro I, Villegas Perez MP, Salvador Silva M, Ruiz Gomez JM, Vidal Sanz M: Retinal ganglion cell death after different transient periods of pressure-induced ischemia and survival intervals: a quantitative in vivo study. Invest Ophthalmol Vis Sci 1996, 37:2002-2014.
92. 92 Buchi ER: Cell death in the rat retina after a pressure-induced ischaemia-reperfusion insult: an electron microscopic study: I: ganglion cell layer and inner nuclear layer. Exp Eye Res 1992, 55:605-613.
93. 93 Adachi M, Takahashi K, Nishikawa M, Miki H, Uyama M: High intraocular pressure-induced ischemia and reperfusion injury in the optic nerve and retina in rats. Graefes Arch Clin Exp Ophthalmol 1996, 234:445-451.
94. 94 Osborne NN, Larsen A, Barnett NL: Influence of excitatory amino acids and ischemia on rat retinal choline acetyltransferase-containing cells. Invest Ophthalmol Vis Sci 1995, 36:1692-1700.
95. 95 Osborne NN, Larsen AK, Barnett NL, Wood J, Cazevieille C: Use of immunohistochemistry to follow the localisation of GABA during retinal ischaemia. In Retinal Degeneration and Regeneration. Edited by Kato S, Osborne NN, Tamai M. Amsterdam: Kugler Publications; 1996:23-29.
96. 96 Nash MS, Osborne NN: Assessment of Thy-1 mRNA levels as an index of retinal ganglion cell damage. Invest Ophthalmol Vis Sci 1998, in press.
97. 97 Osborne NN: Memantine reduces alterations to the mammalian retina, in situ, induced by ischaemia. Vis Neurosci 1998, in press.
98. 98 Grilli M, Pizzi M, Memo M, Spano P: Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 1996, 274:1383-1385.
99. 99 O'Neill EA: A new target for aspirin. Nature 1998, 396:15-16.
100. 100 Ko HW, Park KY, Kim H, Han PL, Kim YU, Gwag BJ, Choi EJ: Ca2+-mediated activation of c-Jun N-terminal kinase and nuclear factor kappa B by NMDA in cortical cell cultures. J Neurochem 1998, 71:1390-1395.
101. 101 Hirano F, Tanaka H, Miura T, Hirano Y, Okamoto K, Makino Y, Makino I: Inhibition of NF-kB-dependent transcription of human immunodeficiency virus 1 promoter by a phosphodiester compound of vitamin C and vitamin E, EPC-K1. Immunopharmacology 1998, 39:31-38.
102. 102 Lezoualc'h F, Sparapani M, Behl C: N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kB. J Pineal Res 1998, 24:168-178.
103. 103 Cazevieille C, Osborne NN: Retinal neurones containing kainate receptors are influenced by exogenous kainate and ischaemia while neurones lacking these receptors are not: melatonin counteracts the effects of ischaemia and kainate. Brain Res 1997, 755:91-100.
104. 104 Osborne N, Nash M, Wood J: Melatonin counteracts apoptosis in cultured human retinal pigment epithelium cells induced by experimental ischaemia. Invest Ophthalmol Vis Sci 1998, 39:2374-2383.
105. 105 Siu AW, Reiter RJ, To CH: The efficacy of vitamin E and melatonin as antioxidants against lipid peroxidation in rat retinal homogenates. J Pineal Res 1998, 24:239-244.
106. 106 Rainsford KD: Aspirin and the Salicylates. Boston: Butterworths; 1984.
107. 107 Maynard KI, Arango PM, Chen D, Ogilvy CS: Acetylsalicylate administered during simulated ischemia reduces the recovery of neuronal function in the in vitro rabbit retina. Neurosci Lett 1998, 249:159-162.
108. 108 Kendler BS: Melatonin: media hype or therapeutic breakthrough? Nurse Pract 1997, 22:66-67.
109. 109 Guardiola Lemaitre B: Toxicology of melatonin. J Biol Rhythms 1997, 12:697-706.
110. 110 Hong YG, Riegler JL: Is melatonin associated with the development of autoimmune hepatitis? J Clin Gastroenterol 1997, 25:376-378.
111. 111 Wiechmann AF, O'Steen WK: Melatonin increases photoreceptor susceptibility to light-induced damage. Invest Ophthalmol Vis Sci 1992, 33:1894-1902.
112. 112 Vorwerk CK, Gorla MSR, Dreyer EB: The Chinese restauranteur's role in glaucoma: an experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Surv Ophthalmol 1998, in press. The finding that glutamate levels are elevated in the vitreous humors of glaucoma patients and the implications of this are discussed in detail in this review.
113. 113 Weber M, Bonaventure N, Sahel JA: Protective role of excitatory amino acid antagonists in experimental retinal ischemia. Graefes Arch Clin Exp Ophthalmol 1995, 233:360-365.
114. 114 Olney J, Price M, Salles KS, Labruyere J, Frierdich G: MK-801 powerfully protects against N-methyl-D-aspartate neurotoxicity. Eur J Pharmacol 1987, 141:357-361.
115. 115 Chaudhary P, Ahmed F, Sharma SC: MK801: a neuroprotectant in rat hypertensive eyes. Brain Res 1998, 792:154-158.
116. 116 Osborne N, Quack G: Memantine stimulates inositol phosphates production in neurones and nullifies N-methyl-D-aspartate-induced destruction of retinal neurones. Neurochem Int 1992, 21:329-336.
117. 117 Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB: Chronic low-dose glutamate is toxic to retinal ganglion cells: toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996, 37:1618-1624.
118. 118 Klockgether T, Loschmann PA, Wullner U: New medical and surgical treatments for Parkinson's disease. Curr Opin Neurol 1994, 7:346-352.
119. 119 Osborne NN, Cazevieille C, Wood JP, Nash MS, Pergande G, Block F, et al.: Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen Pharmacol 1998, 30:255-263.
120. 120 Lei SZ, Pan ZH, Aggarwal SK, Chen HS, Hartman J, Sucher NJ, Lipton SA: Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron 1992, 8:1087-1099.
121. 121 Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA: Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995, 92:7162-7166.
122. 122 Zeevalk GD, Nicklas WJ: Action of the anti-ischemic agent ifenprodil on N-methyl-D-aspartate and kainate-mediated excitotoxicity. Brain Res 1990, 522:135-139.
123. 123 Zeevalk GD, Nicklas WJ: Developmental differences in antagonism of NMDA toxicity by the polyamine site antagonist ifenprodil. Brain Res Dev Brain Res 1992, 65:147-155.
124. 124 Dogan A, Rao AM, Baskaya MK, Rao VL, Rastl J, Donaldson D, Dempsey Rj: Effects of ifenprodil, a polyamine site NMDA receptor antagonist, on reperfusion injury after transient focal cerebral ischemia. J Neurosurg 1997, 87:921-926.
125. 125 Kaiser HJ, Flammer J, Messmer C, Stumpfig D, Hendrickson P: Thirty-month visual field follow-up of glaucoma patients treated with beta-blockers. J Glaucoma 1992, 1:153-155.
126. 126 Collignon Brach J: Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol 1994, 38(suppl):S149-155.
127. 127 Kaiser HJ, Fiammer J, Stumpfig D, Hendrickson P: Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Surv Ophthalmol 1994, 38(suppl):S156-159; discussion S160.
128. 128 Drance SM: A comparison of the effects of betaxolol, timolol and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma 1998, 7:247-252.
129. 129 Hester RK, Chen Z, Becker EJ, McLaughlin M, DeSantis L: The direct vascular relaxing action of betaxolol, carteolol and timolol in porcine long posterior ciliary artery. Surv Ophthalmol 1994, 38(suppl):S125-134.
130. 130 Carenini AB, Sibour G, Boles Carenini B: Differences in the longterm effect of timolol and betaxolol on the pulsatile ocular blood flow. Surv Ophthalmol 1994, 38(suppl):S118-124.
131. 131 Harris A, Spaeth GL, Sergott RC, Katz LJ, Cantor LB, Martin BJ: Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. Am J Ophthalmol 1995, 120:168-175.
132. 132 Yu DY, Su EN, Cringle SJ, Alder VA, Yu PK, Desantis L: Effect of betaxolol. timolol and nimodipine on human and pig retinal arterioles. Exp Eye Res 1998, 67:73-81.
133. 133 Hoste AM, Sys SU: Calcium channel-blocking activity of propanolol and betaxolol in isolated bovine retinal microartery. J Cardiovasc Pharmacol 1998, 32:390-396.
134. 134 Osborne NN, Cazevieille C, Carvalho AL, Larsen AK, DeSantis L: In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res 1997, 751:113-123. In vivo experiments were performed in rats by elevating the IOP for 45 minutes to induce ischemia. The retina was assessed to be damaged after 3 days of reperfusion by electroretinography and immunohistochemistry and these effects were counteracted by intraperitoneal injection of betaxolol before ischemia. In vitro experiments showed that betaxolol also prevented changes to rabbit retinas induced by ionotropic glutamate receptor agonists and oxygen/glucose deprivation.
135. 135 Kitada Y: Betaxolol, a beta 1-adrenoceptor antagonist, inhibits Ca(2+)-induced contraction in skinned renal artery of the dog. Jpn J Pharmacol 1996, 70:191-194.
136. 136 Setoguchi M, Ohya Y, Abe I, Fujishima M: Inhibitory action of betaxolol, a beta 1-selective adrenoceptor antagonist, on voltage-dependent calcium channels in guinea-pig artery and vein. Br J Pharmacol 1995, 115:198-202.
137. 137 Harada T, Harada C, Watanabe M, Inoue Y, Sakagawa T, Nakayama N, et al.: Functions of the two glutamate transporters GLAST and GLT-1 in the retina. Proc Natl Acad Sci U S A 1998, 95:4663-4666. This is a very useful study describing the occurrence of multiple functions for GLAST and GLT-1 glutamate transporters in mice retinas. The authors demonstrate that GLAST is required for normal signal transduction between photoreceptors and bipolar cells and that both GLAST and GLT-1 play a neuroprotective role during ischemia in the retina.